VIM-2–producing Multidrug-ResistantPseudomonas aeruginosaST175 Clone, Spain

Aloush, 2006, Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact., Antimicrob Agents Chemother, 50, 43, 10.1128/AAC.50.1.43-48.2006

Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?, Clin Infect Dis, 34, 634, 10.1086/338782

Queenan, 2007, Carbapenemases: the versatile β-lactamases., Clin Microbiol Rev, 20, 440, 10.1128/CMR.00001-07

Cornaglia, 2011, Metallo-β-lactamases: a last frontier for β-lactams?, Lancet Infect Dis, 11, 381, 10.1016/S1473-3099(11)70056-1

Walsh, 2005, Metallo-beta-lactamases: the quiet before the storm?, Clin Microbiol Rev, 18, 306, 10.1128/CMR.18.2.306-325.2005

Poirel, 2000, Characterization of VIM-2, a carbapenem-hydrolyzing metallo β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France., Antimicrob Agents Chemother, 44, 891, 10.1128/AAC.44.4.891-897.2000

Riccio, 2001, In70 of plasmid pAX22, a blaVIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette., Antimicrob Agents Chemother, 45, 1249, 10.1128/AAC.45.4.1249-1253.2001

Obritsch, 2004, National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002., Antimicrob Agents Chemother, 48, 4606, 10.1128/AAC.48.12.4606-4610.2004

Leibovici, 1998, The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection., J Intern Med, 244, 379, 10.1046/j.1365-2796.1998.00379.x

Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance., Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x

Gutiérrez, 2007, Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals., Antimicrob Agents Chemother, 51, 4329, 10.1128/AAC.00810-07

Rossolini, 2008, First countrywide survey of acquired metallo-β-lactamase in gram-negative pathogens in Italy., Antimicrob Agents Chemother, 52, 4023, 10.1128/AAC.00707-08

Juan, 2008, Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain., Antimicrob Agents Chemother, 52, 3589, 10.1128/AAC.00465-08

Peña, 2007, Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications., Clin Microbiol Infect, 13, 1026, 10.1111/j.1469-0691.2007.01784.x

Riera, 2011, Pseudomonas aeruginosa carbapenem resistance mechanism in Spain: impact on the activity of imipenem, meropenem and doripenem., J Antimicrob Chemother, 66, 2022, 10.1093/jac/dkr232

Viedma, 2009, Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum b-lactamases GES-1 and GES-5 in Spain., Antimicrob Agents Chemother, 53, 4930, 10.1128/AAC.00900-09

Cantón, 2000, Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing., J Clin Microbiol, 38, 1339, 10.1128/JCM.38.4.1339-1346.2000

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, vol. 26, no. 3. 16th informational supplement. M100–S16. Wayne (PA): The Institute; 2006.

Tenover, 1995, Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing., J Clin Microbiol, 33, 2233, 10.1128/JCM.33.9.2233-2239.1995

Curran, 2004, Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa., J Clin Microbiol, 42, 5644, 10.1128/JCM.42.12.5644-5649.2004

Pournaras, 2003, Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4., J Antimicrob Chemother, 51, 1409, 10.1093/jac/dkg239

Gibb, 2002, Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7)., Antimicrob Agents Chemother, 46, 255, 10.1128/AAC.46.1.255-258.2002

Crespo, 2004, Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia., J Clin Microbiol, 42, 5094, 10.1128/JCM.42.11.5094-5101.2004

Ryoo, 2009, Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital., Diagn Microbiol Infect Dis, 63, 115, 10.1016/j.diagmicrobio.2008.08.019

Deplano, 2007, Emergence and dissemination of multidrug resistant clones of Pseudomonas aeruginosa producing VIM-2 metallo-beta-lactamase in Belgium., Euro Surveill, 12

Lolans, 2005, First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States., Antimicrob Agents Chemother, 49, 3538, 10.1128/AAC.49.8.3538-3540.2005

Castanheira, 2009, Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, −5, −6, and −11 and the newly characterized VIM-18)., Antimicrob Agents Chemother, 53, 1225, 10.1128/AAC.01011-08

García-Castillo, 2011, Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals., J Clin Microbiol, 49, 2905, 10.1128/JCM.00753-11

Cholley, 2011, Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types., J Clin Microbiol, 49, 2578, 10.1128/JCM.00102-11

Nemec, 2010, Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic., Res Microbiol, 161, 234, 10.1016/j.resmic.2010.02.002

Libisch, 2009, Identification of two multidrug-resistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary., Curr Microbiol, 58, 111, 10.1007/s00284-008-9285-7

Elias, 2010, Nosocomial outbreak of VIM-2 metallo-β-lactamase producing Pseudomonas aeruginosa associated with retrograde urography., Clin Microbiol Infect, 16, 1494, 10.1111/j.1469-0691.2010.03146.x

Pagani, 2005, Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase., J Clin Microbiol, 43, 3824, 10.1128/JCM.43.8.3824-3828.2005

Duljasz, 2009, First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria., Antimicrob Agents Chemother, 53, 2221, 10.1128/AAC.01573-08

Acosta, 2011, Multidrug-resistant Acinetobacter baumannii harboring OXA-24 carbapenemase, Spain., Emerg Infect Dis, 17, 1064, 10.3201/eid1706.091866

Tam, 2008, Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint., Clin Infect Dis, 46, 862, 10.1086/528712

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 22nd informational supplement. M100–S22. Wayne (PA): The Institute; 2012.